Top Markets
Coin of the day
Shanghai Shyndec Pharmaceutical Co., Ltd. Shanghai Shyndec Pharmaceutical Co., Ltd.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420
Rank in Stocks #7203
Shanghai Shyndec Pharmaceutical Co., Ltd., established in 1996 and... Shanghai Shyndec Pharmaceutical Co., Ltd., established in 1996 and headquartered in Shanghai, China, operates as a pharmaceutical enterprise. The company focuses on the global production of various drug formulations. Its primary therapeutic areas of specialization include anti-infectives, cardiovascular and cerebrovascular treatments, oncology, metabolic disorders, and endocrine system conditions.
Share Price
$1.25
Market Cap
$1.68B
Change (1 day)
0.00%
Change (1 year)
-20.47%
Country
CN
Trade Shanghai Shyndec Pharmaceutical Co., Ltd. (600420)

Category

P/E ratio for Shanghai Shyndec Pharmaceutical Co., Ltd. (600420)
P/E ratio as of 2026 TTM: 0
According to Shanghai Shyndec Pharmaceutical Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Shanghai Shyndec Pharmaceutical Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.